Literature DB >> 19171561

Should NICE's threshold range for cost per QALY be raised? Yes.

Adrian Towse1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19171561     DOI： 10.1136/bmj.b181

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  23 in total

1.  NICE wobbles.

Authors:  Alan Maynard; Karen Bloor
Journal:  J R Soc Med       Date:  2009-06       Impact factor: 5.344

Review 2.  Global implementation of genomic medicine: We are not alone.

Authors:  Teri A Manolio; Marc Abramowicz; Fahd Al-Mulla; Warwick Anderson; Rudi Balling; Adam C Berger; Steven Bleyl; Aravinda Chakravarti; Wasun Chantratita; Rex L Chisholm; Vajira H W Dissanayake; Michael Dunn; Victor J Dzau; Bok-Ghee Han; Tim Hubbard; Anne Kolbe; Bruce Korf; Michiaki Kubo; Paul Lasko; Erkki Leego; Surakameth Mahasirimongkol; Partha P Majumdar; Gert Matthijs; Howard L McLeod; Andres Metspalu; Pierre Meulien; Satoru Miyano; Yaakov Naparstek; P Pearl O'Rourke; George P Patrinos; Heidi L Rehm; Mary V Relling; Gad Rennert; Laura Lyman Rodriguez; Dan M Roden; Alan R Shuldiner; Sukdeb Sinha; Patrick Tan; Mats Ulfendahl; Robyn Ward; Marc S Williams; John E L Wong; Eric D Green; Geoffrey S Ginsburg
Journal:  Sci Transl Med       Date:  2015-06-03       Impact factor: 17.956

3.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

4.  How much should the NHS pay for a QALY?

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 5.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

6.  Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?

Authors:  Lesley Chim; Patrick J Kelly; Glenn Salkeld; Martin R Stockler
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

Authors:  Sanjib Saha; Ulf-G Gerdtham; Pia Johansson
Journal:  Int J Environ Res Public Health       Date:  2010-08-09       Impact factor: 3.390

8.  Bariatric surgery - can we afford to do it or deny doing it?

Authors:  Hutan Ashrafian; Ara Darzi; Thanos Athanasiou
Journal:  Frontline Gastroenterol       Date:  2011-04

9.  Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Authors:  Mark Ritchie; Hiltrud Liedgens; Mark Nuijten
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

10.  The social value of a QALY: raising the bar or barring the raise?

Authors:  Cam Donaldson; Rachel Baker; Helen Mason; Michael Jones-Lee; Emily Lancsar; John Wildman; Ian Bateman; Graham Loomes; Angela Robinson; Robert Sugden; Jose Luis Pinto Prades; Mandy Ryan; Phil Shackley; Richard Smith
Journal:  BMC Health Serv Res       Date:  2011-01-11       Impact factor: 2.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.